Our strategic focus is to complete the pivotal Phase 3 clinical trial of eDSP, called NEAT (Neurologic Effects of eDSP on Subjects with A-T), to evaluate the safety and efficacy of eDSP for the treatment of Ataxia-Telangiectasia (A-T). A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder with currently no approved therapeutic treatments in any global market for this rare pediatric disease.
As of July 16, 2025, Quince completed enrollment of our pivotal Phase 3 clinical trial of eDSP for the treatment of A-T. A total of 105 participants were enrolled, including 83 participants in the six to nine year-old primary analysis population and 22 participants aged 10 years or older. We expect to report topline results from our Phase 3 NEAT study in the first quarter of 2026.
The U.S. Food and Drug Administration granted Fast Track designation for our eDSP System for the treatment of patients with A-T, underscoring the high unmet medical need as there are currently no approved therapeutic treatments for A-T.